Navigation Links
Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009
Date:5/11/2009

Remote Magnetic Navigation prominently featured on the HRS 2009 program

ST. LOUIS, May 11 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) said today that the Heart Rhythm 2009 formal program contains 21 podium and poster presentations in which its Niobe system is either featured or discussed regarding the treatment of complex cardiac arrhythmias. These presentations include new efficacy data on the use of Stereotaxis' partnered magnetic irrigated catheter at centers in Copenhagen and Hamburg.

Xu Chen, MD from Rigshospitalet in Copenhagen will present "Acute and long-term outcomes of remote magnetic navigation for ablation of atrial fibrillation using a magnetic irrigated ablation catheter" at a session beginning at 10:30am on Friday, May 15, in Room 162. At the same session, Erik Weissner of Asklepios Klinik St. Georg in Hamburg will present "Magnetically navigated remote pulmonary vein isolation utilizing the second generation 3.5 mm magnetic irrigated tip catheter."

Also, Tamas Szili-Torok, MD of Erasmus Medical Center in Rotterdam and Jinjin Wu, MD of the German Heart Center in Munich will present at Stereotaxis Booth # 778 their experiences with the Niobe Remote Magnetic Navigation System and the treatment of arrhythmias in children. These booth presentations are separate from their independent conference presentations on the same subjects.

At Stereotaxis' booth, Dr. Szili-Torok will speak at 10:00am on Friday; his presentation is titled, "Magnetic Navigation for the Treatment of Pediatric Complex Congenital Arrhythmias." Dr. Wu will present at 3:00pm on Friday with "Mapping of Atrial Tachycardia: Remote Navigation in Post-Operative Patients with Congential Heart Disease." These presentations will provide a forum for clinicians to share their pediatric experiences and techniques, and demonstrate the growing interest of pediatric electrophysiologists in adding magnetic navigation to their cardiology services.

Against this backdrop of clinical experience, Stereotaxis' Booth # 778 will showcase the simplicity, safety, and efficacy of the Niobe Remote Magnetic Navigation system, the enhanced productivity and procedural efficiency enabled by Navigant 3.0 with QuikCAS, and the full Odyssey information management solution. This includes the new Odyssey Workstation 3.0 software and the Odyssey Cinema(TM) data management system for remote viewing and recording of live interventional cases. This showcase will provide the most comprehensive interactive demonstration of the full Odyssey solution to date, providing clinicians with an opportunity to experience how Odyssey can enhance their institutions' EP practice:

  • At two clinical forums during the conference, participants will be able to view and control the playback of complete EP cases on laptops connected to the Odyssey Cinema server, underscoring the unprecedented opportunities for training and sharing of best practices enabled by this peerless technology.
  • An Odyssey Connect network link will enable clinicians to use an Odyssey Workstation in Booth # 778 to remotely control a catheter in a Niobe lab in the company's St. Louis headquarters, 1,200 miles away.
  • The Odyssey Workstation will be available with a new, state-of-the-art QuadHD display. Quad HD provides four times the resolution of prior, high-definition displays, providing an incredible level of patient detail.

"With our Odyssey Cinema product, we believe that we are building the first true networked clinical environment that can improve care, enhance training and education, maximize cath-lab efficiency, promote best practices and drive hospital referrals," said Michael P. Kaminski, Stereotaxis' President and Chief Executive Officer. "We are pleased with the progress we've made and will continue our investment in Odyssey sales and marketing to take full advantage of our first mover position in this space.

"We also look forward to highlighting the impressive new clinical results that have been achieved with the Niobe Remote Magnetic Navigation system. Stereotaxis' routine appearance in so many presentations and posters speaks to the widespread adoption of our technology by leading electrophysiologists, both for daily clinical practice and scientific discovery. This year we are seeing an important increase in utilization for applications such as ventricular tachycardia and navigation of the unpredictable anatomy associated with congenital heart disease. Our customers report that magnetic navigation is uniquely suited to these important market segments, highlighting the platform's versatility in every chamber. We are confident that it will continue to transform interventional medicine well into the future."

Heart Rhythm 2009, the Heart Rhythm Society's 30th Annual Scientific Sessions, will be held at the Boston Convention and Exhibition Center, May 13 -- 16, 2009.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
2. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
3. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
4. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
5. Stereotaxis Receives $20 Million in Additional Loan Commitments
6. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
7. Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
8. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
9. Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases
10. Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. Stereotaxis Reports Record First Quarter Orders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: